Pharmaceutical Spending
Global pharmaceutical spending reached ~$1.6 trillion in 2024 — more than tripling since 2000. The US accounts for ~45% of global spending despite being 4% of world population. Per-capita drug spending varies about 6× across the OECD countries shown. New high-cost drug categories — GLP-1s, oncology, gene therapies — have driven much of recent growth.
Key insights
US prices are the global outlier
On the same drug, the US typically pays 2-4× what European or Asian healthcare systems pay. Drivers: limited government negotiation (the Medicare Drug Price Negotiation Program starts modestly in 2026), high list prices supporting research and dividends, complex rebate systems, and tolerance for high prices in the US market. The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for the first time — first 10 drugs negotiated for 2026.
GLP-1 spending surged
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) together generated about $45B in 2024 revenue. The category is reshaping pharma — diabetes/obesity drugs are now the second-largest therapeutic area after oncology. Cardiovascular benefits, reduced alcohol intake, possible cognitive effects are all being investigated. Manufacturing capacity was the binding constraint through 2024, prompting major capex commitments by Novo Nordisk and Eli Lilly; price and coverage are now the bigger limits.
Cell and gene therapies push pricing frontiers
Approved CAR-T cancer therapies cost $400k-500k per treatment. Approved gene therapies for sickle cell (Casgevy, Lyfgenia) and Duchenne muscular dystrophy (Elevidys) cost $2-3M per treatment. Hemgenix for hemophilia B: $3.5M. These prices reflect manufacturing complexity, small patient populations, and high R&D costs. Accountability for outcomes and value remains contested in payer negotiations.
Pharmaceutical spending per capita — selected OECD (2024)
USD PPP per person per year
Show data table
| USD per capita | |
|---|---|
| USA | 1300 |
| Switzerland | 1115 |
| Germany | 876 |
| Japan | 830 |
| Canada | 720 |
| France | 725 |
| Italy | 610 |
| Australia | 675 |
| OECD avg | 665 |
| Spain | 580 |
| UK | 470 |
| Korea | 710 |
| Poland | 300 |
| Mexico | 210 |
Key Finding: US is the clear outlier; Germany, Switzerland, Japan in next tier; UK and Mediterranean countries lowest among advanced economies.
Top therapeutic areas by global spending (2024)
USD billions
Show data table
| USD billions | |
|---|---|
| Oncology | 225 |
| Diabetes / GLP-1 | 140 |
| Immunology | 140 |
| Cardiovascular | 75 |
| Anti-infective | 85 |
| Pain | 65 |
| CNS | 75 |
| Respiratory | 55 |
| Vaccines | 50 |
| HIV | 45 |
Key Finding: Oncology and diabetes (with the GLP-1 surge) now dominate global drug spending.
Methodology & caveats
List vs net prices
US drug prices have two layers: 'list' or wholesale acquisition cost (WAC), and 'net' after manufacturer rebates to PBMs and insurers. The two can differ by 50%+ for many drugs. Public reports often quote list prices; actual flows are at net. International comparisons should specify which is used.
Definitions of pharmaceutical spending
OECD definitions: pharmaceuticals consumed inside hospitals are sometimes counted in hospital spending, not pharma spending. Outpatient prescriptions vs hospital drugs vs over-the-counter — different countries count differently. IQVIA's market-based numbers and OECD's national-accounts numbers can differ by 20%+. Cross-country comparisons need careful methodology specification.
Generic share
Generic drugs (off-patent, low margin) account for 70-90% of prescriptions in most advanced economies but only 10-25% of dollar spending. Brand-name and biologic drugs dominate spending. As more drugs come off-patent, the spending share continues to shift toward newer, higher-cost categories (oncology, immunology) even as the volume share moves to generics.
Why the same spending has several totals
IQVIA's $1.6 trillion is based on manufacturer sales valued at invoice prices and leaves out many rebates, so its US figure overstates what payers actually spend. OECD figures come from national health accounts and are usually retail-only, leaving out medicines given in hospitals, which is why oncology-heavy systems look cheaper than they are. PPP adjustment also matters: it shrinks the gap between rich and middle-income countries, because a dollar buys more local services but not necessarily more imported medicine.
What would change the picture
The Medicare negotiated prices that took effect in 2026 will test how far list prices fall for older drugs. The US has also pushed most-favoured-nation pricing deals with manufacturers, which could raise launch prices abroad as much as lower them at home. Semaglutide patents begin to expire in several large markets from 2026, and biosimilars are entering immunology, so the same category can fall fast once exclusivity ends.
Cite this page
GlobeChart. “Pharmaceutical Spending.” Last updated 2026-10-31. https://globechart.com/health/pharmaceutical-spending/
Please also credit the original publisher named under each chart: OECD Health Statistics 2024, IQVIA; IQVIA Global Use of Medicines 2024. Spotted an error? Tell us.